

CADUS PHARMACEUTICAL CORP  
Form SC 13D/A  
June 06, 2003

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**(Rule 13d-101)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND  
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)**

**(Amendment No. 8)<sup>1</sup>**

Cadus Pharmaceutical Corporation

---

(Name of Issuer)

Common Stock, \$0.01 par value

---

(Title of Class of Securities)

127639102

---

(CUSIP Number)

Sandra Leung

Bristol-Myers Squibb Company

345 Park Avenue

New York, NY 10154

(212) 546-4000

---

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 30, 2003

---

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box " ".

(Continued on following pages)

(Page 1 of 11)

---

<sup>1</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 127639102

SCHEDULE 13D

Page 2 of 11

1. Name of Reporting Person, S.S. or I.R.S. Identification No. of above person

Bristol-Myers Squibb Company

I.R.S. Employer Identification Number 22-079-0350

2. Check the Appropriate Box if a Member of a Group

(a)

(b)

3. SEC Use Only

4. Source of Funds

WC

5. Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

Delaware

NUMBER OF  
SHARES

7. Sole Voting Power

BENEFICIALLY  
OWNED BY

627,500

OWNED BY

8. Shared Voting Power

EACH

REPORTING

0

PERSON

9. Sole Dispositive Power

WITH

627,500

---

10. Shared Dispositive Power

0

---

11. Aggregate Amount Beneficially Owned by Each Reporting Person

627,500

---

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

---

13. Percent of Class Represented by Amount in Row (11)

4.8%

---

14. Type of Reporting Person

CO

---

CUSIP No. 127639102

SCHEDULE 13D

Page 3 of 11

This Amendment No. 8 is being filed to amend Item 5 of this Schedule 13D.

Item 1. Security and Issuer.

The class of equity securities to which this Statement relates is the Common Stock, par value \$0.01 per share (the Common Stock ), of Cadus Pharmaceutical Corporation, a Delaware corporation (the Issuer ), which has its principal executive offices at 767 Fifth Avenue, New York, NY 10153.

Item 2. Identity and Background.

This Amendment is being filed by Bristol-Myers Squibb Company, a Delaware corporation (the Company ). The Company conducts its principal business and maintains its principal office at 345 Park Avenue, New York, NY 10154. The Company is a worldwide pharmaceutical and related health care products company.

The name, business address, present principal occupation or employment and citizenship of each executive officer and director of the Company is set forth on Schedule A which is incorporated herein by reference.

During the past five years, neither the Company nor, to the best knowledge of the Company, any of its executive officers or directors (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3. Source and Amount of Funds or Other Consideration.

In July 1994, the Issuer and the Company entered into a research collaboration, whereby the Company agreed to make an initial equity investment of \$12,500,000 in the Issuer's Series B Preferred Stock. The Company made an additional equity investment of \$5,000,000 in the Issuer's Series B Preferred Stock in September 1995 upon the Issuer achieving a research milestone. Both equity investments came out of the working capital of the Company.

CUSIP No. 127639102

SCHEDULE 13D

Page 4 of 11

On July 17, 1996, the Issuer completed an initial public offering of its Common Stock with a per share offering price of \$7.00. The Company made an additional equity investment of \$2,500,000, acquiring 355,000 shares of Common Stock. The purchase price for this investment came out of the working capital of the Company.

Item 4. Purpose of Transaction.

The Company acquired the Common Stock of the Issuer for the purpose of making an investment in the Issuer and not with the view to, or for resale in connection with, any distribution thereof. The Common Stock of the Issuer was initially acquired in connection with a research collaboration between the Company and the Issuer which expired in July 1999.

The Company and the Issuer are parties to a letter agreement (the Letter Agreement ) concerning the Company's shares of the Common Stock. Such Letter Agreement is filed as an exhibit hereto and is incorporated herein by reference. The Letter Agreement includes certain notice requirements and transfer restrictions with respect to the Company's shares of the Common Stock. Subject to market conditions and the Letter Agreement, the Company may, in its sole discretion, sell all or a portion of its shares of Common Stock from time to time in open market transactions or otherwise.

Item 5. Interest in Securities of the Issuer.

(a) To the best knowledge of the Company, as of May 30, 2003, the Company is the beneficial owner of 627,500 shares of Common Stock of the Issuer or approximately 4.8% of the Common Stock of the Issuer currently outstanding.

(b) The Company has the sole power to vote and dispose of all the shares of the Common Stock of the Issuer that it owns.

(c) Schedule B attached hereto describes the transactions in shares of Common Stock that were effected by the Company since the most recent filing on Schedule 13D.

Except as set forth in this Item 5 and on Schedule B attached hereto which is incorporated herein by reference, neither the Company nor, to the best knowledge of the Company, any of its officers or directors owns any shares of Common Stock.

Except as set forth in Item 3 and on Schedule B attached hereto which is incorporated herein by reference, neither the Company nor, to the best knowledge of the

CUSIP No. 127639102

SCHEDULE 13D

Page 5 of 11

Company, any of its executive officers or directors has effected any transaction in shares of Common Stock during the past sixty (60) days.

(d) Not Applicable.

(e) On May 30, 2003, the Company ceased to be the beneficial owner of more than five percent of the Issuer's Common Stock.

Item 6. Contracts, Arrangements, Understanding or Relationships With Respect to Securities of the Issuer.

The Preferred Stock Purchase Agreement, together with First Amendment thereto, filed as an exhibit hereto is incorporated herein by reference. Except as set forth in such Agreement or the Letter Agreement, neither the Company nor, to the best knowledge of the Company, any of its officers or directors have entered into any contracts, arrangements, understandings or relationships (legal or otherwise) with respect to the Common Stock of the Issuer.

Item 7. Material to be Filed as Exhibits.

1. Preferred Stock Purchase Agreement dated as of July 26, 1994 between Issuer and the Company concerning Series B Preferred Stock, together with the First Amendment thereto dated as of October 31, 1995 (incorporated herein by reference to Exhibit No. 10.8 to Registration Statement No. 333-4441 on Form S-1).
2. Letter Agreement dated March 23, 1999 between the Issuer and the Company (incorporated herein by reference to Exhibit No. 2 to Amendment No. 2 to this Schedule 13D).

CUSIP No. 127639102

SCHEDULE 13D

Page 6 of 11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Dated: June 5, 2003

BRISTOL-MYERS SQUIBB COMPANY

By: /s/ SANDRA LEUNG

---

**Sandra Leung**

**Corporate Secretary**

CUSIP No. 127639102

SCHEDULE 13D

Page 7 of 11

## SCHEDULE A

The following information sets forth the name, citizenship, business address and present principal occupation of each of the directors and executive officers of the Company. Except as set forth below, each of the directors and executive officers of the Company is a citizen of the United States of America. Each of the Company's executive officer's business address is 345 Park Avenue, New York, New York 10154, unless otherwise indicated.

Directors of Bristol-Myers Squibb Company

<u>Name and Business Address</u>	<u>Present Principal Occupation</u>
Peter R. Dolan	Chairman and Chief Executive Officer
Bristol-Myers Squibb Company	
345 Park Avenue	
New York, NY 10154	
Robert E. Allen	Retired Chairman and Chief Executive
AT&T Corp. Officer	
180 Park Avenue	
Room 1E38	
Florham Park, NJ 07932	
Lewis B. Campbell	Chairman, President and Chief Executive Officer
Textron Inc.	
40 Westminster Street	
Providence, RI 02903-2596	
Vance D. Coffman	Chairman and Chief Executive Officer
Lockheed Martin Corporation	
6801 Rockledge Drive	
Bethesda, MD 20817	
Ellen V. Futter	President

Edgar Filing: CADUS PHARMACEUTICAL CORP - Form SC 13D/A

American Museum of Natural History

Central Park West at 79th Street

New York, NY 10024

CUSIP No. 127639102

SCHEDULE 13D

Page 8 of 11

Name and Business Address

Present Principal Occupation

Louis V. Gerstner, Jr.

Retired Chairman and Chief Executive Officer

IBM Corporation

New Orchard Road

Armonk, NY 10504

Laurie H. Glimcher, M.D.

Irene Heinz Given Professor of Immunology,

Harvard Medical School and

Harvard School of Public Health and Professor

Harvard School of Public Health

of Medicine, Harvard Medical School

Dept. of Immunology and Infectious Diseases

651 Huntington Avenue, FXB-2

Boston, MA 02115

Leif Johansson

President, AB Volvo and Chief Executive Officer,

AB Volvo

The Volvo Group

SE-40508

Goteborg, Sweden

Citizen of Sweden

James D. Robinson III

Chairman and Chief Executive Officer

RRE Investors

126 East 56th Street, 22<sup>nd</sup> Floor

New York, NY 10022

Louis W. Sullivan, M.D.

President Emeritus

Morehouse School of Medicine

720 Westview Drive, S.W.

Atlanta, GA 30310-1495

Executive Officers of Bristol-Myers Squibb Company

Name

Present Principal Occupation

Peter R. Dolan

Chairman and Chief Executive Officer

Edgar Filing: CADUS PHARMACEUTICAL CORP - Form SC 13D/A

Lamberto Andreotti

Senior Vice President and President, International

Citizen of Italy

Harrison M. Bains, Jr.

Vice President, Tax & Treasury

CUSIP No. 127639102

SCHEDULE 13D

Page 9 of 11

Name	Present Principal Occupation
Stephen E. Bear	Senior Vice President, Human Resources
Andrew G. Bodnar, M.D.	Senior Vice President, Strategy and Medical & External Affairs
Andrew R. J. Bonfield	Senior Vice President and Chief Financial Officer
Citizen of the United Kingdom	Chief Marketing Officer and President, Global Marketing
Wendy L. Dixon	
Citizen of the United Kingdom and	
the United States of America	Executive Vice President and President, Americas
Donald J. Hayden, Jr.	Senior Vice President, Corporate and Business Development
Tamar D. Howson	Vice President and Corporate Secretary Executive Vice President and General Counsel
Sandra Leung	President, U.S. Primary Care
John L. McGoldrick	Chief Scientific Officer and President, Pharmaceutical Research Institute
Dean J. Mitchell	Senior Vice President, Global Clinical and Pharmaceutical Development
Citizen of the United Kingdom	Senior Vice President, Corporate and Environmental Affairs
James B. D. Palmer, M.D.	Vice President and Controller
Citizen of the United Kingdom and	
the United States of America	Senior Vice President, Global Clinical and Pharmaceutical Development
Elliot Sigal, M.D., Ph.D.	Senior Vice President, Corporate and Environmental Affairs
John L. Skule	Vice President and Controller
David L. Zabor	

CUSIP No. 127639102

SCHEDULE 13D

Page 10 of 11

SCHEDULE BShares of Common Stock Owned

None.

Transactions in Shares of Common Stock

Sales on the open market by the Company of the Issuer's Common Stock since the most recent filing on Schedule 13D are described below:

<u>Date</u>	<u>Number of Shares</u>	<u>Price Per Share</u>
04/11/03	70,000	\$1.30
04/21/03	5,500	\$1.25
04/28/03	7,540	\$1.26
05/07/03	29,000	\$1.31
05/13/03	4,000	\$1.27
05/29/03	8,000	\$1.27
05/30/03	55,500	\$1.29

CUSIP No. 127639102

SCHEDULE 13D

Page 11 of 11

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Document</u>
1	Preferred Stock Purchase Agreement dated as of July 26, 1994 between Cadus Pharmaceutical Corporation and Bristol-Myers Squibb Company, together with the First Amendment thereto dated as of October 31, 1995 (incorporated herein by reference to Exhibit No. 10.8 to Registration Statement No. 333-4441 on Form S-1).
2	Letter Agreement dated March 23, 1999 between the Issuer and the Company (incorporated herein by reference to Exhibit No. 2 to Amendment No. 2 to this Schedule 13D).